Immune checkpoint inhibitors (ICIs) target the cytotoxic T lymphocyte antigen 4 (CTLA-4)/CD28/programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis, leading to immune activation in the tumor microenvironment (2, 3). Here, CD274 is linked to neoplasm.